Excited to share our most recent cover story about repatriating generic drugs, APIs and ingredients.
In 2020, Meagan Parrish wrote an award-winning piece for us on this topic when it was still very fresh: https://lnkd.in/eiqU7zN8
That got me wondering: Four years later, where do we stand? The government has spent billions of dollars on the pharma reshoring movement, has it paid off? And more importantly, what's next?
Those questions led to the creation of this piece, in which I aimed to give a comprehensive overview of where the industry stands with its domestic manufacturing efforts and what needs to happen to sustain progress.
The government’s investments into generic drugs and APIs have created an air of excitement surrounding the westward migration of manufacturing. Now comes arguably the most vital phase of U.S. domestic manufacturing efforts — figuring out where to get the most lasting bang for our reshoring bucks. With the pandemic finally in our rearview, the U.S. has what many industry insiders see as a golden opportunity to candidly assess pharma’s reshoring progress — and create a more formal plan for supply chain resilience.
Read the intro here: https://lnkd.in/gK_4UM3Z
Part 1 here: https://lnkd.in/ggpkaTfq
Part 2 here: https://lnkd.in/gz39wdST
#reshoring #domesticmanufacturing #BARDA #ASPR #pharmamanufacturing
Marta E. Wosinska, Ph.D., Bikash Chatterjee, Eric Edwards, MD, PhD, Salvatore Mascia, Kevin Webb, Phlow, CONTINUUS Pharmaceuticals
![Mining pharma's reshoring rush]()
Mining pharma's reshoring rush
pharmamanufacturing.com
Tags, Nameplates , ID Products
2moGreat Post